XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.2
Equity Method Investment and Other Equity Investments - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 16, 2024
Apr. 30, 2024
Feb. 20, 2024
Feb. 13, 2024
Jul. 29, 2025
Jun. 30, 2025
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Schedule Of Equity Method Investments [Line Items]                        
Gain on deconsolidation               $ 0 $ 126,294 $ 0 $ 126,294  
Net loss from equity method investments               20,189 7,925 35,745 7,925  
Prepaid expenses and other current assets           $ 60,240   60,240   60,240   $ 34,869
Research and development liabilities               111,231 114,695 222,662 255,667  
Other current liabilities           65,916   65,916   65,916   33,071
Amortization of asset               700 600 1,300 1,200  
Gondola Bio, LLC                        
Schedule Of Equity Method Investments [Line Items]                        
Investments contributed           60,000   60,000   60,000    
Gain on deconsolidation $ 52,000                      
Equity investment 50,000         $ 25,600   25,600   25,600   41,500
Difference of between fair value of equity investment and underlying equity in net assets $ 23,900                      
Net loss from equity method investments               $ 9,100   $ 15,900    
Equity ownership percentage approximately 45.50%         29.20%   29.20%   29.20%    
Investors committed amount           $ 300,000   $ 300,000   $ 300,000    
Aggregate cash contributed           42,500   42,500   42,500    
Investors contribution fair value $ 50,000                      
TheRas, Inc                        
Schedule Of Equity Method Investments [Line Items]                        
Payment for private equity financing with external investors   $ 200,000                    
Percentage of ownership reduced for private equity financing   37.90%                    
Gain on deconsolidation   $ 126,300                    
Equity investment   124,900       $ 82,400   82,400   82,400   102,200
Difference of between fair value of equity investment and underlying equity in net assets   $ 49,600                    
Net loss from equity method investments               $ 11,100 7,900 $ 19,800 7,900  
Equity ownership percentage approximately           35.50%   35.50%   35.50%    
Transition Service Aggrement | Gondola Bio, LLC                        
Schedule Of Equity Method Investments [Line Items]                        
Research and development liabilities               $ 500   $ 1,200    
Other current liabilities           $ 2,400   2,400   2,400   1,200
Transition Service Aggrement | TheRas, Inc                        
Schedule Of Equity Method Investments [Line Items]                        
Prepaid expenses and other current assets           400   400   400   500
Other income               300 800 700 800  
Research and development liabilities               0 $ 300 0 $ 300  
Transition Service Agreement And Sublease Agreement | Gondola Bio, LLC                        
Schedule Of Equity Method Investments [Line Items]                        
Prepaid expenses and other current assets           $ 4,500   4,500   4,500   $ 3,200
Operating expenses               1,900   2,700    
Transition Service Agreement And Sublease Agreement | Gondola Bio, LLC                        
Schedule Of Equity Method Investments [Line Items]                        
Other income               2,700   5,400    
IPR&D | Gondola Bio, LLC                        
Schedule Of Equity Method Investments [Line Items]                        
Amortization of asset               300   600    
IPR&D | TheRas, Inc                        
Schedule Of Equity Method Investments [Line Items]                        
Amortization of asset               $ 600   $ 1,200    
BridgeBio Pharma, LLC | LianBio                        
Schedule Of Equity Method Investments [Line Items]                        
Warrants exercised     347,569                  
Common stock held                   5,350,361    
Net proceeds received as special cash dividends             $ 25,700          
Realized net gains from investment             $ 1,800          
Special cash dividend declared per share       $ 4.8   $ 0.43            
Depositary fees per share       $ 0.05   $ 0.05            
BridgeBio Pharma, LLC | LianBio | Subsequent Event                        
Schedule Of Equity Method Investments [Line Items]                        
Net proceeds received as special cash dividends         $ 2,300